cagrisema novo nordisk news - Search News

Novo Nordisk shares plummet

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

New York Post on MSN · 14h

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

CNN on MSN · 14h

Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.

21h

Novo Nordisk to explore CagriSema weight-loss potential in new trial

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

17h

Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

15h

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

17h

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...

Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

10hon MSN

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results